Intercept study



Keywords: us,intercept,study,liverdiseasedrug,japan,united states,healthcare services (trbc),generic and specialty pharmaceuticals (trbc),equities markets,company news,science,healthcare (trbc),healthcare providers and services (trbc),asia,pacific,volatile shares,hot stocks,general news,pharmaceuticals (trbc),health,medicine,pharmaceuticals and medical research (trbc),biotechnology,pharmaceuticals (legacy),biotechnology and medical research (trbc),americas
Description: Intercept Pharmaceuticals Inc's drug to treat liver disease caused by fat buildup was found effective in a trial, paving the way for it to become the first approved treatment for the chronic condition.

n">(Reuters) - Intercept Pharmaceuticals Inc's drug to treat liver disease caused by fat buildup was found effective in a trial, paving the way for it to become the first approved treatment for the chronic condition.

The company's shares nearly quadrupled to a life high of $305 on Thursday morning on the Nasdaq, valuing the company at about $6 billion.

Intercept said it had stopped the trial after the drug showed statistically significant improvement in patients, compared with a placebo, in a review by an independent safety committee.

The trial tested the drug, obeticholic acid, in patients with non-alcoholic steatohepatitis (NASH), a form of liver inflammation.

Analysts said the news came as a surprise to investors, who had previously focused on the drug as a treatment for primary biliary cirrhosis, an autoimmune disease in which bile ducts in the liver are destroyed. The drug is being tested for the condition in a late-stage study.

"We didn't expect this data until the fourth quarter," Wedbush analyst Liana Moussatos said. "It's a huge opportunity for the company as there are over 10 million patients worldwide."

Moussatos said Intercept could tie up with Big Pharma companies to conduct a late-stage trial of the drug. Intercept could also conduct a late-stage trial with its partner Dainippon Sumitomo Pharma, which is testing the drug in Japan, she said.

Obeticholic acid, Intercept's lead drug, is also being tested in mid-stage studies to treat bile acid diarrhea and portal hypertension, which is high blood pressure in veins that transport blood from the gastrointestinal tract and spleen to the liver.

Intercept said the safety committee made the recommendation after reviewing liver biopsy data from about half of the 283 patients enrolled in the mid-stage trial.

There is currently no specific treatment for NASH, according to the U.S. National Institutes of Health.

To manage the disease, patients are recommended to maintain a healthy weight, follow a balanced diet, increase physical activity and avoid alcohol.






Photogallery Intercept study:


Trail user intercept study data model and results


Trail user intercept study data model and results


Trail user intercept study data model and results


trail-user-intercept-study- ...


A study of the microphysical processes in a numerically simulated ...


Students' use of the x-intercept as an instance of a transitional ...


Barebacking, the Internet, and Harm Reduction: An Intercept Survey ...


Sexual Risk Behavior and Venues for Meeting Sex Partners: An ...


Bias in Measures of Implicit Racial Bias | Human Varieties


Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin ...


05102|Welcome Intercept - Powered by Kayako fusion Help Desk Software


21% are shoppers with upper household incomes of more than ...


AP Chemistry Study Guide- Kinetics


Irv Arons' Journal: Apeliotus Vision Science's AdaptDx Device for ...


The "Snowden is Ready to Come Home!" Story: a Case Study in ...


Presentation "Vegetation Transects San Pedro Creek Study. Two ...


Evidence of Student Learning - Kelley Turner's Portfolio


hypaper


FRB: The High-Frequency Effects of U.S. Macroeconomic Data ...


Website Feedback Surveys & Forms | Site Intercept | Qualtrics